Orthocell Ltd (AU:OCC)
ASX:OCC
Want to see AU:OCC full AI Analyst Report?
Top Page
Orthocell Ltd
(Sydney:OCC)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.86
▲(6.17% Upside)
Action:ReiteratedDate:11/19/25
Orthocell Ltd faces significant challenges with profitability and cash flow, as reflected in its financial performance score. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall stock score.
Positive Factors
Low leverage
A very low debt-to-equity ratio provides durable financial flexibility, reducing refinancing and interest burden risk. That conservatism supports continued R&D and clinical programs over months, giving management runway to commercialise products without immediate pressure to raise costly debt.
Negative Factors
Negative profitability
Sustained negative net and EBIT margins and a negative ROE indicate the company is not yet profitable. Over the medium term, persistent unprofitability pressures cash reserves and can force dilution or cutbacks in R&D and commercial activities if revenue growth does not accelerate to offset margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A very low debt-to-equity ratio provides durable financial flexibility, reducing refinancing and interest burden risk. That conservatism supports continued R&D and clinical programs over months, giving management runway to commercialise products without immediate pressure to raise costly debt.
Read all positive factors
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$237.39M
Dividend YieldN/A
Average Volume (3M)820.75K
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue Growth49.03%
EPS Growth-232.68%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding271,307,950
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.21Price Target Upside48.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$12.23M
Orthocell Ltd Business Overview & Revenue Model
Company Description
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived coll...
How the Company Makes Money
Orthocell makes money primarily by commercialising its medical products and related services. Key revenue streams include: (1) Product sales: Sales of its nerve repair product Remplir to hospitals/clinicians and/or through distribution partners, g...
Orthocell Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
| Gross Profit | 3.50M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
| EBITDA | -15.31M | -13.43M | -11.68M | -10.34M | -11.52M | -11.67M |
| Net Income | -12.48M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
| Total Assets | 59.80M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
| Cash, Cash Equivalents and Short-Term Investments | 44.37M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
| Total Debt | 835.79K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
| Total Liabilities | 18.64M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
| Stockholders Equity | 41.16M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
| Free Cash Flow | -12.21M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
| Operating Cash Flow | -12.05M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
| Investing Cash Flow | -42.26M | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
| Financing Cash Flow | 30.84M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Orthocell Ltd Technical Analysis
Positive
0.81
Price Trends
0.87
Positive
0.95
Positive
1.09
Negative
Market Momentum
0.04
Negative
67.29
Neutral
83.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Positive. The current price of 0.81 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.87, and below the 200-day MA of 1.09, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 67.29 is Neutral, neither overbought nor oversold. The STOCH value of 83.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:OCC.
Orthocell Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$75.99M | -7.57 | -179.37% | ― | ― | 24.59% | |
52 Neutral | AU$2.85B | ― | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$11.48M | -0.46 | -218.76% | ― | 76.94% | 42.95% | |
44 Neutral | AU$8.16M | -2.68 | -29.91% | ― | 82.28% | 13.33% | |
42 Neutral | AU$28.32M | -6.84 | -49.25% | ― | ― | 25.00% | |
41 Neutral | AU$237.39M | -12.98 | -44.80% | ― | 49.03% | -232.68% |
* Healthcare Sector Average
AU:OCC
Orthocell Ltd
0.88
-0.72
-44.97%
AU:CYP
Cynata Therapeutics Limited
0.32
0.13
64.10%
AU:1AI
Living Cell Technologies
0.01
<0.01
40.00%
AU:MSB
Mesoblast Limited
2.20
0.41
22.56%
AU:TRP
Tissue Repair Ltd
0.14
-0.07
-32.50%
AU:CMB
Regeneus Ltd.
0.42
0.20
90.91%
Orthocell Ltd Corporate Events
Orthocell logs first Remplir sales in Canada, advancing global nerve repair rollout
Apr 30, 2026
Orthocell has recorded its first commercial sales of Remplir in Canada, following Health Canada approval and the appointment of distributors that provide majority national coverage in a nerve repair market worth about US$75 million. The company ha...
Orthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study
Apr 27, 2026
Orthocell has reported new real-world evidence showing its Remplir nerve repair device achieved an overall treatment success rate of 89.7% across 78 procedures in 66 patients, with no post-treatment complications or adverse effects recorded. The s...
Orthocell Flags Risks and Confidentiality in Q3 FY26 Investor Briefing
Apr 19, 2026
Orthocell Ltd, a regenerative medicine and medical technology company specialising in cell-based therapies for musculoskeletal and nerve repair, targets clinicians and healthcare providers seeking advanced orthopaedic and reconstructive treatment ...
Orthocell records first U.S. military hospital case for Remplir after DoD–VA approval
Apr 16, 2026
Orthocell has completed the first U.S. Department of Defense and Veterans Affairs surgical case using its Remplir nerve repair product, just days after gaining approval to supply it across those hospital networks. The procedure, performed at a mil...
Orthocell Wins U.S. Defence and VA Access for Remplir Nerve Repair Device
Apr 14, 2026
Orthocell has secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks, giving it access to 51 military hospitals and 170 VA medical centres. The company ...
Orthocell Reports Lapse of 17,379 Retention Rights in Capital Structure Update
Apr 14, 2026
Orthocell Ltd has notified the market of a change to its capital structure via an Appendix 3H filing, confirming the lapse of 17,379 OCCAAH retention rights. The rights ceased on 14 April 2026 after the conditions attached to these securities were...
Orthocell to Outline March-Quarter Results and Remplir Rollout in Investor Webinar
Apr 14, 2026
Orthocell Ltd will release its quarterly results for the period ended 31 March 2026 on 20 April and host an investor webinar the same day, led by its chair, chief executive and chief financial officer. The briefing will cover financial performance...
Orthocell courts investors with biotech presentation as global product rollout advances
Mar 31, 2026
Orthocell Ltd, a Perth-based regenerative medicine specialist, is expanding a suite of products aimed at repairing bone, nerve, tendon and cartilage injuries, anchored by collagen medical devices and autologous cell therapies. Its lead products, i...
Orthocell reports lapse of 16,567 retention rights, trimming potential equity
Mar 16, 2026
Orthocell Ltd has notified the market that 16,567 retention rights, classified as OCCAAH securities, have lapsed after conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these conditional secu...
Orthocell Issues New Retention and Performance Rights Under Employee Incentive Plan
Mar 16, 2026
Orthocell Ltd has issued 654,963 retention rights and 240,065 performance rights as unquoted securities under its employee incentive scheme, effective 16 March 2026. The new rights, which are subject to transfer restrictions and will not be quoted...
Orthocell Taps LEDA for UK Launch of Remplir Nerve Repair Device
Mar 9, 2026
Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir nerve repair device in the United Kingdom, a move that underpins its strategy to penetrate the UK and EU peripheral nerve repair market estimated at US$750 mill...
Orthocell director Michael McNulty increases on‑market shareholding
Feb 25, 2026
Orthocell Limited has reported a change in the holdings of director Michael McNulty, who maintains both direct and indirect interests in the company’s securities through personal holdings, a family trust structure and his spouse. The disclos...
Orthocell Director Increases Shareholding Through On-Market Purchase
Feb 25, 2026
Orthocell has disclosed a change in director John Van Der Wielen’s interests following an on‑market purchase of 32,500 ordinary shares for $31,337. The transaction increases his direct equity exposure while leaving his 4,000,000 unlist...
Orthocell posts record half-year revenue as global expansion gains pace
Feb 23, 2026
Orthocell has reported record first-half FY26 revenue of $6.2 million, up 48% year-on-year, driven by rising adoption of its Striate+ and Remplir products and improved gross margins of 55%. The company remains loss-making, with a $5.2 million net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.